Skip to main content
Top
Published in: AIDS Research and Therapy 1/2024

Open Access 01-12-2024 | Obesity | Research

Brief communication: body composition and hidden obesity in people living with HIV on antiretroviral therapy

Authors: K. Konishi, H. Nakagawa, T. Asaoka, Y. Kasamatsu, T. Goto, M. Shirano

Published in: AIDS Research and Therapy | Issue 1/2024

Login to get access

Abstract

Background

Increased incidence of lifestyle diseases as side-effects of antiretroviral therapy (ART) have been reported in people living with HIV (PLWH). Few studies have evaluated obesity and hidden obesity in Japanese PLWH and their association with ART. In order to provide more appropriate drug selection and lifestyle guidance, we investigated the relationship between the effects of HIV infection and ART on the body composition of Japanese PLWH.

Methods

PLWH who visited the outpatient clinic and had body composition measured using the body composition analyzer InBody 570 were included in this study. Medications, comorbidities, and blood test data were obtained. Body mass index (BMI), body fat percentage, and skeletal muscle mass index (SMI) were measured.

Results

In this study, 543 patients were included. Based on body shape, patients were classified into a thin group (13), normal weight group (14), hidden obesity group (158), apparent obesity group (14), and obesity group (218). Compared with the normal weight group, the hidden obesity group had a higher prevalence of comorbidities and a lower SMI.

Conclusions

PLWH are more likely to have obesity than the general population, indicating that hidden obesity is common even among those with a normal BMI. It is important to measure body fat percentage along with body weight, as hidden obesity can be missed. Further investigation of the effects of ART on body composition is needed.
Literature
8.
go back to reference Yoshiike N, Nishi N, Matsushima S, Ito C, Ikeda Y, Kashihara H, et al. Obesity degree and diabetes, hypertension based on body Mass Index, epidemiological examination—by associated—multicenter study with the risk factor of hyperlipidemia. J Jpn Soc Study Obes. 2000;6:4–17. Yoshiike N, Nishi N, Matsushima S, Ito C, Ikeda Y, Kashihara H, et al. Obesity degree and diabetes, hypertension based on body Mass Index, epidemiological examination—by associated—multicenter study with the risk factor of hyperlipidemia. J Jpn Soc Study Obes. 2000;6:4–17.
9.
go back to reference Japan Society for the Study of Obesity. Guidelines for the treatment of obesity. Tokyo: Life Science Publishing; 2016. Japan Society for the Study of Obesity. Guidelines for the treatment of obesity. Tokyo: Life Science Publishing; 2016.
12.
go back to reference Yamada C, Kishimoto N, Motegi S, Kikuchi E, Ogata T, Kuroda E, et al. [Health screening/ningen dock can reduce age-related risks! The results of anti-aging checkups at Tokai University Tokyo Hospital over a decade]. Health Eval Promot. 2017;44:523–30.CrossRef Yamada C, Kishimoto N, Motegi S, Kikuchi E, Ogata T, Kuroda E, et al. [Health screening/ningen dock can reduce age-related risks! The results of anti-aging checkups at Tokai University Tokyo Hospital over a decade]. Health Eval Promot. 2017;44:523–30.CrossRef
Metadata
Title
Brief communication: body composition and hidden obesity in people living with HIV on antiretroviral therapy
Authors
K. Konishi
H. Nakagawa
T. Asaoka
Y. Kasamatsu
T. Goto
M. Shirano
Publication date
01-12-2024
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2024
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-024-00599-3

Other articles of this Issue 1/2024

AIDS Research and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine